Enliven Therapeutics, Inc./$ELVN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Enliven Therapeutics, Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Ticker
$ELVN
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
65
ISIN
US29337E1029
Website
ELVN Metrics
BasicAdvanced
$1.3B
-
-$1.93
1.10
-
Price and volume
Market cap
$1.3B
Beta
1.1
52-week high
$24.11
52-week low
$13.30
Average daily volume
655K
Financial strength
Current ratio
21.065
Quick ratio
20.724
Long term debt to equity
0.105
Total debt to equity
0.231
Profitability
EBITDA (TTM)
-109.948
Effective tax rate (TTM)
-0.25%
Management effectiveness
Return on assets (TTM)
-21.36%
Return on equity (TTM)
-31.30%
Valuation
Price to book
3.87
Price to tangible book (TTM)
3.87
Price to free cash flow (TTM)
-15.106
Free cash flow yield (TTM)
-6.62%
Free cash flow per share (TTM)
-150.80%
Growth
Earnings per share change (TTM)
0.58%
Bulls say / Bears say
Enliven Therapeutics maintains a strong financial position with $313.4 million in cash and equivalents as of December 31, 2024, providing a cash runway into mid-2027, enabling sustained investment in research and development. (Enliven Therapeutics)
The company's lead candidate, ELVN-001, demonstrated a 44.4% major molecular response rate in a Phase 1 trial for chronic myeloid leukemia (CML) patients by 24 weeks, indicating promising efficacy. (StockTitan)
Enliven's ELVN-002 program is progressing with multiple ongoing Phase 1 trials targeting HER2+ cancers, with data expected in the second half of 2025, potentially expanding the company's oncology portfolio. (Enliven Therapeutics)
Enliven reported a net loss of $89.0 million for the full year 2024, an increase from $71.6 million in 2023, reflecting rising operational expenses. (Enliven Therapeutics)
Research and development expenses rose to $80.8 million in 2024 from $64.6 million in 2023, indicating higher costs associated with advancing clinical programs. (Enliven Therapeutics)
General and administrative expenses increased to $23.8 million in 2024 from $19.0 million in 2023, suggesting escalating overhead costs. (Enliven Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Enliven Therapeutics, Inc. stock?
Enliven Therapeutics, Inc. (ELVN) has a market cap of $1.3B as of July 11, 2025.
What is the P/E ratio for Enliven Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Enliven Therapeutics, Inc. (ELVN) stock is 0 as of July 11, 2025.
Does Enliven Therapeutics, Inc. stock pay dividends?
No, Enliven Therapeutics, Inc. (ELVN) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Enliven Therapeutics, Inc. dividend payment date?
Enliven Therapeutics, Inc. (ELVN) stock does not pay dividends to its shareholders.
What is the beta indicator for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. (ELVN) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.